🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Canada / NCT06899724
Starting soon Not applicable

Methoxyflurane for Analgesia During Hysteroscopy

NCT06899724 · tracked via the Priya Life Science Canada tracker
Sponsor
Dr. John A. Thiel Medical Professional Corporation
Phase
Not applicable
Started
2025-06-01
Last updated
2025-03-28

Condition(s) studied

Analgesia

Investigational drug(s) / intervention(s)

Anesthetics, Inhalation →Intravenous Sedatives with or Without Analgesia

Anesthetics, Inhalation: Inhaled analgesia

Intravenous Sedatives with or Without Analgesia: IV Fentanyl and midazolam

Study summary

This study is to assess the non-inferiority of using inhaled methoxyflurane (MOF) versus intravenous conscious sedation with fentanyl and midazolam on women's perception of pain, during hysteroscopy and/or polypectomy in an outpatient setting. The researchers will determine whether the participants receiving the inhaled MOF (experimental group) achieve similar clinical effects in reduction of pain and ability to complete the procedure. Women's perception of pain will be recorded on a scale from 0 to 10 using the numeric rating scale (NRS).

Eligibility

Sex
FEMALE
Min age
25 Years
Max age
75 Years
Healthy volunteers
Accepted
Inclusion Criteria: Abnormal uterine Bleeding requiring hysteroscopy Postmenopausal bleeding requiring hysteroscopy Exclusion Criteria: Uterine or patient characteristics that preclude hysteroscopy Submucosal fibroids requiring myomectomy Past allergic reaction to fentanyl or midazolam BMI \> 42 Contraindications precluding use of intravenous sedation (sleep apnea) Lack of patient consent History of malignant hyperthermia History of significant renal or hepatic disease

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
University of Saskatchewan Saskatoon Saskatchewan

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06899724 on ClinicalTrials.gov ↗ ← All trials in Canada